Ironwood offers upbeat PhIII data details on linaclotide

Ironwood and Forest Labs took the stage at the Digestive Disease Week conference to spell out their promising Phase III data on linaclotide, Ironwood's closely-watched treatment for irritable bowel syndrome with constipation. The therapy achieved statistically significant results for the primary as well as all secondary endpoints. "The results of these trials suggest that linaclotide may provide an attractive option for millions of patients suffering from chronic constipation," said investigator Anthony Lembo, M.D. Ironwood release

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i